2016

2016年

1. Synthesis of the CYP24A1 major metabolite of 2α-[2-(tetrazol-2-yl)ethyl]-1α,25-dihydroxyvitaminD3.
   Takano M, Yasuda K, Tohyama E, Higuchi E, Sakaki T, Kittaka A.
   J Steroid Biochem Mol Biol. 164, 40-44. (2016)
   
   
2. 　　 　 Novel screening system for high-affinity ligand of heredity vitamin D-resistant rickets-associated vitamin D receptor mutant R274L using bioluminescent sensor.
   Mano H, Nishikawa M, Yasuda K, Ikushiro S, Saito N, Sawada D, Honzawa S, Takano M, Kittaka A, Sakaki T.
   J Steroid Biochem Mol Biol. 167:61-66. (2016)
   
   
3. Sequential hydroxylation of vitamin D2 by a genetically engineered CYP105A1.
   Hayashi K, Yasuda K, Yogo Y, Takita T, Yasukawa K, Ohta M, Kamakura M, Ikushiro S, Sakaki T.
   Biochem Biophys Res Commun, 473: 853-858 (2016)
   
   
4. Synthesis, metabolism, and biological activity of 2-[3-(tetrazolyl)propyl]-1α,25-dihydroxy-19-norvitamin D3.
   Takano M, Yasuda K, Higuchi E, Tohyama E, Takeuchi A, Sakaki T, Kittaka A.
   J. Steroid Biochem. Mol. Biol. 164:40-44 (2016)
   
   
5. Evaluation of Double Point Modified Analogues of 1,25-dihydroxyvitamin D2 as Potential Anti-leukemic Agents.
   Corcoran A, Nadkarni S, Yasuda K, Sakaki T, Brown G, Kutner A, Marcinkowska E;
   Biological International Journal of Molecular Sciences, 17: pii: E91 (2016)
   
   
6. Biosynthesis of Drug Glucuronide Metabolites in the Budding Yeast Saccharomyces cerevisiae.
   Ikushiro S, Nishikawa M, Masuyama Y, Shouji T, Fujii M, Hamada M, Nakajima N, Finel M, Yasuda K, Kamakura M, Sakaki T.
   Mol Pharm. 13: 2274-82 (2016)